Moving towards disease modification in inflammatory bowel disease therapy

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Inflammatory bowel diseases (IBD) are chronic, disabling conditions with limited long-term remission rates using anti-tumor necrosis factor (TNF)-α agents.
• Current treatments often fail to achieve mucosal healing or deep remission, necessitating advanced therapeutic strategies.

Purpose of the Study:

• To review current and emerging trends in IBD therapy.
• To emphasize the importance of achieving deep remission and mucosal healing for altering disease course.
• To identify promising new therapeutic targets for IBD patients refractory to anti-TNF-α therapy.

Main Methods:

• Review of current literature on IBD treatment strategies.
• Analysis of emerging therapeutic targets and agents.
• Evaluation of new indices for assessing long-term patient outcomes and trial endpoints.

Main Results:

• Deep remission is crucial for preventing long-term disability and bowel damage in IBD.
• New disability indices and Crohn's disease damage scores aid in evaluating treatment efficacy.
• Early intervention with disease-modifying anti-IBD drugs (DMAIDs) is recommended for high-risk patients.

Conclusions:

• Tofacitinib, vedolizumab, and ustekinumab are promising agents for IBD patients who have not responded to anti-TNF-α therapy.
• The ultimate goal of IBD therapy is to modify the disease course, improve quality of life, and prevent disability.